Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says

MT Newswires Live

2025/12/11

Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.

Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.

Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products "multi-billion-dollar opportunities."

The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.

Price: 19.59, Change: +1.15, Percent Change: +6.21

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2590534392"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590534392\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590534392?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590534392","market":"fut","top_or_hot":-1,"title":"Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (DYN) biggest catalyst moving forward is the read-through from competitor <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.</p><p>Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.</p><p>Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"</p><p>The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.</p><p>Price: 19.59, Change: +1.15, Percent Change: +6.21</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-11 01:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (DYN) biggest catalyst moving forward is the read-through from competitor <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.</p><p>Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.</p><p>Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"</p><p>The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.</p><p>Price: 19.59, Change: +1.15, Percent Change: +6.21</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009354923.USD","symbol_name":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590534392","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590534392","pubTimestamp":1765388276,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4127":"投资银行业与经纪业","BK4588":"碎股","RNA":"Atrium Therapeutics","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","DYN":"戴纳基","OPY":"奥本海默控股","BK4139":"生物科技"},"translate_title":"奥本海默表示，Dyne Therapeutics最大的催化剂是Avidity Biosciences 2026年下半年的DM1读数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DYN":1.5,"OPY":1.5,"RNA":1.5},"content_text":"Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.Price: 19.59, Change: +1.15, Percent Change: +6.21","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}